HRP20241053T1 - Pirimidinski inhibitori jak, namijenjeni liječenju kožnih bolesti - Google Patents
Pirimidinski inhibitori jak, namijenjeni liječenju kožnih bolesti Download PDFInfo
- Publication number
- HRP20241053T1 HRP20241053T1 HRP20241053TT HRP20241053T HRP20241053T1 HR P20241053 T1 HRP20241053 T1 HR P20241053T1 HR P20241053T T HRP20241053T T HR P20241053TT HR P20241053 T HRP20241053 T HR P20241053T HR P20241053 T1 HRP20241053 T1 HR P20241053T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- group
- compound according
- image
- Prior art date
Links
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000017520 skin disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 28
- 150000003839 salts Chemical class 0.000 claims 27
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 201000004624 Dermatitis Diseases 0.000 claims 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 4
- 201000008937 atopic dermatitis Diseases 0.000 claims 4
- 208000037896 autoimmune cutaneous disease Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 claims 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 201000011486 lichen planus Diseases 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 claims 1
- 125000001963 4 membered heterocyclic group Chemical group 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 206010001764 Alopecia scarring Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 claims 1
- 208000011738 Lichen planopilaris Diseases 0.000 claims 1
- 206010024434 Lichen sclerosus Diseases 0.000 claims 1
- 239000004909 Moisturizer Substances 0.000 claims 1
- 201000009053 Neurodermatitis Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000031709 Skin Manifestations Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 229960004675 fusidic acid Drugs 0.000 claims 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000001333 moisturizer Effects 0.000 claims 1
- 229960003128 mupirocin Drugs 0.000 claims 1
- 229930187697 mupirocin Natural products 0.000 claims 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 claims 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 208000017940 prurigo nodularis Diseases 0.000 claims 1
- 208000037851 severe atopic dermatitis Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837827P | 2019-04-24 | 2019-04-24 | |
| PCT/US2020/029466 WO2020219640A1 (en) | 2019-04-24 | 2020-04-23 | Pyrimidine jak inhibitors for the treatment of skin diseases |
| EP20727424.2A EP3959213B1 (en) | 2019-04-24 | 2020-04-23 | Pyrimidine jak inhibitors for the treatment of skin diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20241053T1 true HRP20241053T1 (hr) | 2024-11-08 |
Family
ID=70779856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20241053TT HRP20241053T1 (hr) | 2019-04-24 | 2020-04-23 | Pirimidinski inhibitori jak, namijenjeni liječenju kožnih bolesti |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11439641B2 (https=) |
| EP (1) | EP3959213B1 (https=) |
| JP (1) | JP7482152B2 (https=) |
| AR (1) | AR118767A1 (https=) |
| CA (1) | CA3135388A1 (https=) |
| ES (1) | ES2994097T3 (https=) |
| HR (1) | HRP20241053T1 (https=) |
| HU (1) | HUE067909T2 (https=) |
| PL (1) | PL3959213T3 (https=) |
| TW (1) | TW202106681A (https=) |
| WO (1) | WO2020219640A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202001706RA (en) | 2017-10-27 | 2020-03-30 | Theravance Biopharma R&D Ip Llc | Pyrimidine compound as jak kinase inhibitor |
| WO2020108613A1 (zh) * | 2018-11-30 | 2020-06-04 | 江苏豪森药业集团有限公司 | 杂芳类衍生物调节剂、其制备方法和应用 |
| PL3958969T3 (pl) | 2019-04-24 | 2024-05-20 | Theravance Biopharma R&D Ip, Llc | Estrowe i węglanowe związki pirymidynowe jako inhibitory kinaz |
| CN116390922B (zh) * | 2020-10-21 | 2025-07-18 | 珠海联邦制药股份有限公司 | 硒杂环类化合物及其应用 |
| WO2022094174A1 (en) * | 2020-10-30 | 2022-05-05 | Children's Hospital Medical Center | Compositions and methods for the treatment of esophageal conditions |
| JP2024516299A (ja) * | 2021-05-03 | 2024-04-12 | インサイト・コーポレイション | 結節性痒疹の治療のためのルキソリチニブ |
| UA129643C2 (uk) | 2021-05-03 | 2025-06-18 | Інсайт Корпорейшн | Інгібітори шляху jak1 для лікування вузлуватого свербця |
| WO2023202706A1 (zh) * | 2022-04-21 | 2023-10-26 | 南京明德新药研发有限公司 | 硒杂环类化合物的盐型和晶型及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4919934A (en) | 1989-03-02 | 1990-04-24 | Richardson-Vicks Inc. | Cosmetic sticks |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2002022605A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6989385B2 (en) | 2000-12-21 | 2006-01-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US20070179125A1 (en) | 2005-11-16 | 2007-08-02 | Damien Fraysse | Aminopyrimidines useful as kinase inhibitors |
| TW200817391A (en) | 2006-06-30 | 2008-04-16 | Astrazeneca Ab | Novel compounds |
| EP2043651A2 (en) | 2006-07-05 | 2009-04-08 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
| CN104011050A (zh) | 2011-12-22 | 2014-08-27 | 霍夫曼-拉罗奇有限公司 | 作为丝氨酸/苏氨酸激酶抑制剂的2,4-二氨基-嘧啶衍生物 |
| WO2015094803A1 (en) | 2013-12-16 | 2015-06-25 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| NO2721710T3 (https=) | 2014-08-21 | 2018-03-31 | ||
| ES2753159T3 (es) | 2015-05-28 | 2020-04-07 | Theravance Biopharma R&D Ip Llc | Compuestos de naftiridina como inhibidores de quinasa JAK |
| CA3020506A1 (en) | 2016-04-28 | 2017-11-02 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compounds as jak kinase inhibitors |
| CN106588885B (zh) * | 2016-11-10 | 2019-03-19 | 浙江大学 | 2-取代芳环-嘧啶类衍生物及制备和应用 |
| SG11202001706RA (en) | 2017-10-27 | 2020-03-30 | Theravance Biopharma R&D Ip Llc | Pyrimidine compound as jak kinase inhibitor |
| WO2020108516A1 (zh) | 2018-11-27 | 2020-06-04 | 江苏豪森药业集团有限公司 | 含氮杂芳类衍生物调节剂、其制备方法和应用 |
| WO2020108613A1 (zh) | 2018-11-30 | 2020-06-04 | 江苏豪森药业集团有限公司 | 杂芳类衍生物调节剂、其制备方法和应用 |
| PL3958969T3 (pl) * | 2019-04-24 | 2024-05-20 | Theravance Biopharma R&D Ip, Llc | Estrowe i węglanowe związki pirymidynowe jako inhibitory kinaz |
| CN113372364B (zh) | 2020-03-10 | 2024-05-31 | 明慧医药（上海）有限公司 | 一类jak激酶抑制剂及其制备和应用 |
| CN113372351A (zh) | 2020-03-10 | 2021-09-10 | 明慧医药（杭州）有限公司 | 一类jak激酶抑制剂及其制备和应用 |
-
2020
- 2020-04-23 TW TW109113573A patent/TW202106681A/zh unknown
- 2020-04-23 WO PCT/US2020/029466 patent/WO2020219640A1/en not_active Ceased
- 2020-04-23 HR HRP20241053TT patent/HRP20241053T1/hr unknown
- 2020-04-23 US US16/856,283 patent/US11439641B2/en active Active
- 2020-04-23 HU HUE20727424A patent/HUE067909T2/hu unknown
- 2020-04-23 ES ES20727424T patent/ES2994097T3/es active Active
- 2020-04-23 EP EP20727424.2A patent/EP3959213B1/en active Active
- 2020-04-23 PL PL20727424.2T patent/PL3959213T3/pl unknown
- 2020-04-23 CA CA3135388A patent/CA3135388A1/en active Pending
- 2020-04-23 AR ARP200101151A patent/AR118767A1/es not_active Application Discontinuation
- 2020-04-23 JP JP2021562812A patent/JP7482152B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3959213A1 (en) | 2022-03-02 |
| TW202106681A (zh) | 2021-02-16 |
| ES2994097T3 (en) | 2025-01-17 |
| JP7482152B2 (ja) | 2024-05-13 |
| CA3135388A1 (en) | 2020-10-29 |
| PL3959213T3 (pl) | 2024-11-04 |
| HUE067909T2 (hu) | 2024-11-28 |
| US20200338073A1 (en) | 2020-10-29 |
| AR118767A1 (es) | 2021-10-27 |
| WO2020219640A1 (en) | 2020-10-29 |
| JP2022529371A (ja) | 2022-06-21 |
| EP3959213C0 (en) | 2024-06-05 |
| EP3959213B1 (en) | 2024-06-05 |
| US11439641B2 (en) | 2022-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241053T1 (hr) | Pirimidinski inhibitori jak, namijenjeni liječenju kožnih bolesti | |
| HRP20240346T1 (hr) | Esterski i karbonatni spojevi pirimidina kao inhibitori jak-kinaze | |
| EP1971611B1 (en) | Anti-viral compounds | |
| JP4935357B2 (ja) | 新規縮環イミダゾール誘導体 | |
| KR102319857B1 (ko) | P2x7 조절제 | |
| AU2016368317B2 (en) | Inhibitors of influenza virus replication, application methods and uses thereof | |
| AU2018388404B2 (en) | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | |
| AU2018353759B2 (en) | Heterocyclic compound as a protein kinase inhibitor | |
| JP2024028845A (ja) | コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤 | |
| EP3052496B1 (en) | 4-azaindole derivatives | |
| AU2013266110A1 (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
| EP3412669A1 (en) | Tricyclic compound for bromodomain-containing protein inhibitor and preparation, pharmaceutical composition, and application thereof | |
| SA06270020B1 (ar) | مركبات جديدة للاستخدام في علاج حالات العدوى البكترية | |
| EA026497B1 (ru) | 6-алкинилпиридины в качестве миметиков smac | |
| KR20160056896A (ko) | Ｐｉｍ 키나아제 억제제로서 유용한 푸로- 및 티에노-피리딘 카복사미드 화합물 | |
| KR20220027196A (ko) | 이미다조[1,2-a]피리디닐 유도체 및 질병의 치료에서 이것들의 용도 | |
| ME02672B (me) | Fenil-3-aza-bicikl0[3.1.0]heks-3-il-metanoni i njihova primena kao medikament | |
| IL279641B2 (en) | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | |
| CN117466868A (zh) | 双重magl和faah抑制剂 | |
| CA3208951A1 (en) | Pyrazolopyridine derivatives and uses thereof | |
| JP6353899B2 (ja) | ロイコトリエン生成の阻害剤 | |
| KR20140125389A (ko) | Mtor-저해제로서 피리미도옥사조신 유도체 | |
| EP2903983A1 (en) | Inhibitors of viral replication, their process of preparation and their therapeutical uses | |
| CN121399126A (zh) | 具有gpr68调节活性的双环杂芳基酰胺 | |
| WO2024258769A1 (en) | Antimalarial agents |